Literature DB >> 11948030

A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma.

Kenneth B Newman1, Scott Milne, Cathy Hamilton, Kent Hall.   

Abstract

STUDY
OBJECTIVES: To determine the efficacy of albuterol by metered-dose inhaler (MDI) and spacer compared to a nebulizer.
DESIGN: A prospective, open-label study.
SETTING: Large urban emergency department (ED). PATIENTS: All consecutive adult asthma patients over a 2.5-year period.
INTERVENTIONS: ED personnel used a standardized treatment algorithm, which included albuterol administered by nebulization, for patients presenting to the ED during the first 12 months of the study. The treatment algorithm then was switched to one that utilized albuterol administered by MDI/spacer as the primary mode of delivery for the following 18 months. As part of the conversion to MDI/spacer, ED staff counseled patients on self-management and supplied patients with a peak flowmeter, an MDI/spacer, and an inhaled steroid for home use. MEASUREMENTS: Pulmonary function, clinical outcome, laboratory data, and financial data were assembled and analyzed from 2,342 ED visits and 1,420 patients.
RESULTS: While there was no significant difference in hospital admission rates between patients in the MDI/spacer group and the nebulizer group (13.2% and 14.6%, respectively), there was a statistically greater improvement in peak flow rates in the MDI/spacer group (126.8 vs 111.9 L/min, respectively; p = 0.002). The MDI/spacer group also spent significantly less time in the ED (163.6 and 175 min, respectively; p = 0.007), had a lower total albuterol dose (1,125 microg and 6,700 microg, respectively; p < 0.001), and showed a greater improvement in arterial oxygen saturation (p = 0.043). Relapse rates at 14 and 21 days were significantly lower (p < 0.01 and p < 0.05, respectively) among patients treated with the MDI/spacer and were associated with asthma education and the provision of a peak flowmeter, a spacer, and an inhaled corticosteroid for patients' home use.
CONCLUSIONS: Albuterol administered by MDI/spacer is an efficacious and cost-effective alternative to nebulization in adults with acute asthma who present at a large urban ED.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948030     DOI: 10.1378/chest.121.4.1036

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

1.  National Athletic Trainers' Association position statement: management of asthma in athletes.

Authors:  Michael G Miller; John M Weiler; Robert Baker; James Collins; Gilbert D'Alonzo
Journal:  J Athl Train       Date:  2005 Jul-Sep       Impact factor: 2.860

Review 2.  Asthma in the Primary Care Setting.

Authors:  Tianshi David Wu; Emily P Brigham; Meredith C McCormack
Journal:  Med Clin North Am       Date:  2019-05       Impact factor: 5.456

3.  A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma.

Authors:  Katayoon Najafizadeh; Hamid Sohrab Pour; Mojtaba Ghadyanee; Masoud Shiehmorteza; Masoud Jamali; Sayeed Majdzadeh
Journal:  Emerg Med J       Date:  2007-05       Impact factor: 2.740

4.  The Effect of Training Inhalation Technique with or without Spacer on Maximum Expiratory Flow Rate and Inhaler Usage Skills in Asthmatic Patients: A Randomized Controlled Trial.

Authors:  Hashem Rahmati; Fatemeh Ansarfard; Fariba Ghodsbin; Mohammad Ali Ghayumi; Mehrab Sayadi
Journal:  Int J Community Based Nurs Midwifery       Date:  2014-10

Review 5.  The World Anti-Doping Code: can you have asthma and still be an elite athlete?

Authors:  Ken Fitch
Journal:  Breathe (Sheff)       Date:  2016-06

6.  Prescribing patterns of nebulized bronchodilators: A prospective chart review.

Authors:  Julian P Yaxley
Journal:  J Family Med Prim Care       Date:  2016 Apr-Jun

Review 7.  Optimizing the Delivery of Inhaled Medication for Respiratory Patients: The Role of Valved Holding Chambers.

Authors:  R Andrew McIvor; Hollie M Devlin; Alan Kaplan
Journal:  Can Respir J       Date:  2018-04-04       Impact factor: 2.409

8.  Primary Care Management of Asthma Exacerbations or Attacks: Impact of the COVID-19 Pandemic.

Authors:  Monica Fletcher; Thys van der Molen; Warren Lenney; Isabelle Boucot; Bhumika Aggarwal; Emilio Pizzichini
Journal:  Adv Ther       Date:  2022-02-14       Impact factor: 3.845

Review 9.  Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma.

Authors:  Christopher J Cates; Emma J Welsh; Brian H Rowe
Journal:  Cochrane Database Syst Rev       Date:  2013-09-13

10.  Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer.

Authors:  David S Hui; Benny K Chow; Leo C Y Chu; Susanna S Ng; Stephen D Hall; Tony Gin; Matthew T V Chan
Journal:  Chest       Date:  2009-03       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.